Skip to content

Ketamine: all studies

Page 400 of 448: studies 3,991 to 4,000 of 4,475, newest first. Back to the ketamine overview

Research

Introduction to the chemistry and pharmacology of psychedelic drugs

Australian Journal of Chemistry July 4, 2023 Scott R. Walker, Glenn A. Pullella, Matthew Piggott et al. 5 citations

The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has mainly resulted from publicity associated with a number of high-profile investigations into psychedelic-assisted therapy for a range of difficult-to-treat mental health conditions. With many psychedelic substances known, including natural,...

Local Orchestration of Global Functional Patterns Supporting Loss and Restoration of Consciousness in the Primate Brain

bioRxiv (Cold Spring Harbor Laboratory) July 3, 2023 Andrea I. Luppi, Lynn Uhrig, Jordy Tasserie et al. 10 citations preprint

Abstract A central challenge of neuroscience is to elucidate how the orchestration of brain function is modulated by different states of consciousness. Here, we investigate the link between distributed structural and functional brain organisation in functional MRI signals of non-human primates, through bi-directional causal manipulations of consciousness. During varying levels of propofol,...

New Pharmacologic Approaches to the Treatment of Bipolar Depression.

Drugs July 1, 2023 Kamyar Keramatian, Trisha Chakrabarty, Anais DuBow et al. 19 citations

Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primary driver of functional impairment and suicidality in BD. Despite this, there are few effective treatments for BD depression, with only a handful of atypical anti-psychotics and inconsistent evidence for traditional mood stabilizing agents. There have been few...

DOI: 10.1007/s40265-023-01872-x (opens in new tab) Full text (opens in new tab) Mental-health Psychiatric-treatment Bipolar-disorder Depression-therapy +1

Review: The use of functional magnetic resonance imaging (fMRI) in clinical trials and experimental research studies for depression

Frontiers in Neuroimaging June 27, 2023 Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri et al. 26 citations

Functional magnetic resonance imaging (fMRI) is a non-invasive technique that can be used to examine neural responses with and without the use of a functional task. Indeed, fMRI has been used in clinical trials and pharmacological research studies. In mental health, it has been used to identify brain areas linked to specific symptoms but also has the potential to help identify possible...

DOI: 10.3389/fnimg.2023.1110258 (opens in new tab) Major depressive disorder Antidepressant Depression economics Neuroimaging +4

Classics in Chemical Neuroscience: Dextromethorphan (DXM).

ACS Chemical Neuroscience June 21, 2023 Elliot W McClure, R Nathan Daniels

Dextromethorphan (DXM) was introduced in 1958 as the first non-opioid cough suppressant and is indicated for multiple psychiatric disorders. It has been the most used over-the-counter cough suppressant since its emergence. However, individuals quickly noticed an intoxicating and psychedelic effect if they ingested large doses. DXM's antagonism at N-methyl-d-aspartate receptors (NMDAr) is...

DOI: 10.1021/acschemneuro.3c00088 (opens in new tab) Full text (opens in new tab) Dextromethorphan Nmda receptor antagonist Cough Dextrorphan +2

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms

European Neuropsychopharmacology June 21, 2023 Seline Mock, Nicole Friedli, Patrick Pasi et al. 46 citations

Eating disorders are serious illnesses showing high rates of mortality and comorbidity with other mental health problems. Psychedelic-assisted therapy has recently shown potential in the treatment of several common comorbidities of eating disorders, including mood disorders, post-traumatic stress disorder, and substance use disorders. The theorized therapeutic mechanisms of psychedelic-assisted...

DOI: 10.1016/j.euroneuro.2023.05.008 (opens in new tab) Anxiety Anorexia nervosa Bulimia nervosa Eating disorders +7

In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape

Science Advances June 14, 2023 Leor Roseman, Christopher Timmermann, Daniel Golkowski et al. 65 citations

To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically induced macroscale functional reorganization, by relating the regional distribution of 19 neurotransmitter receptors and transporters...

DOI: 10.1126/sciadv.adf8332 (opens in new tab) Pharmacology Neurotransmitter receptor Human brain

Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.

Expert Review of Neurotherapeutics June 1, 2023 Harry A Fagan, David S Baldwin 55 citations

Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry. Current management consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatments and novel anxiolytic drugs are being developed. In this review, the authors first...

Role of Psychedelics in Treatment-Resistant Depression.

Psychiatric Clinics of North America June 1, 2023 Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan 32 citations

There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also...

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Nature Neuroscience June 1, 2023 Rafael Moliner, Mykhailo Girych, Vera Kovaleva et al. 439 citations

Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to...

DOI: 10.1038/s41593-023-01316-5 (opens in new tab) Full text (opens in new tab) Neuroplasticity Brain-derived neurotrophic factor Receptor Neurotrophic factors